EBV-associated colonic B-cell lymphoma following treatment with infliximab for IBD: a new problem?

Abstract

Patients with inflammatory bowel disease who do not respond to steroid therapy often require treatment with immunomodulators in an attempt to achieve a response and maintain remission. However, a major concern and controversy is whether these treatments are putting the patients at a significantly increased risk of developing lymphomas. This case reports a patient with severe ulcerative colitis who had been previously treated with azathioprine and infliximab, and subsequently developed diffuse large B-cell colonic lymphoma.

• Authors: Patrick B Allen, Georgina Laing, Aoife Connolly, Ciaran O'Neill
• Journal: BMJ case reports (BMJ Case Rep) Vol. 2013 (Sep 30 2013) ISSN: 1757-790X [Electronic] England
• PMID: 24081592 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antibodies, Monoclonal
• Gastrointestinal Agents
• Tumor Necrosis Factor-alpha
• Infliximab

Topics

• Aged
• Antibodies, Monoclonal (adverse effects, therapeutic use)
• Colonic Neoplasms (chemically induced, diagnosis)
• Diagnosis, Differential
• Epstein-Barr Virus Infections (chemically induced, diagnosis)
• Gastrointestinal Agents (adverse effects, therapeutic use)
• Herpesvirus 4, Human
• Humans
• Inflammatory Bowel Diseases (drug therapy)
• Infliximab
• Lymphoma, Large B-Cell, Diffuse (chemically induced, diagnosis)
• Male
• Sigmoidoscopy
• Tomography, X-Ray Computed
• Tumor Necrosis Factor-alpha (antagonists & inhibitors)